Results 31 to 40 of about 17,965 (195)

Recurrent Ovarian Cancer with the Involvement of Urinary Organs: is There Place for Secondary Cytoreductive Surgery?

Galician Medical Journal, 2017
The objective of the research was to estimate early and long-term results of secondary cytoreductive surgery performed for recurrent ovarian cancer with involvement of urinary organs. Materials and methods. The study included 62 patients with recurrent
Kateryna Kharchenko
doaj   +1 more source

Multi‐Omics Profiling of High‐Grade Serous Ovarian Cancer Reveals an Inflammation‐Related Lipid Metabolism Subtype Associated With Platinum Resistance

Advanced Science, EarlyView.
Through integrated proteomic and metabolomic profiling, Zhao et al. identified three molecular subtypes of high‐grade serous ovarian cancer. The high‐risk subtype exhibits activated arachidonic acid metabolism and cyclooxygenase‐2 overexpression. This metabolic axis promotes M2‐like macrophage infiltration, which contributes to platinum resistance ...
Yuxi Zhao, Junyi Li, Bo Zheng, Wanshan Liu, Yaru Wang, Shufeng Wang, Ying Cui, Huiqin Guo, Hongxia Wang, Ting Xiao, Kun Qian, Jing Zuo   +11 more
wiley   +1 more source

Clinical efficacy of cytoreductive radical prostatectomy in the treatment of oligometastatic hormone-sensitive prostate cancer

Holistic Integrative Oncology
Objective To investigate the clinical efficacy of cytoreductive surgery in oligometastatic hormone-sensitive prostate cancer (omHSPC). Methods The basic characteristics, treatment strategies and long-term follow-up of 181 patients with omHSPC were ...
Feng Qi, Yihang Xu, Zicheng Xu, Qing Zou
doaj   +1 more source

Advanced low grade serous ovarian cancer: A retrospective analysis of surgical and chemotherapeutic management in two high volume oncological centers

Frontiers in Oncology, 2022
Simple summaryLow-grade serous ovarian cancer (LGSOC) represents an uncommon histotype of serous ovarian cancer (accounting for approximately 5% of all ovarian cancer) with a distinct behavior compared to its high-grade serous counterpart, characterized ...
Paolo Di Lorenzo, Paolo Di Lorenzo, Vincenza Conteduca, Vincenza Conteduca, Emanuela Scarpi, Marco Adorni, Francesco Multinu, Annalisa Garbi, Ilaria Betella, Tommaso Grassi, Tommaso Bianchi, Giampaolo Di Martino, Andrea Amadori, Paolo Maniglio, Isabella Strada, Silvestro Carinelli, Marta Jaconi, Giovanni Aletti, Giovanni Aletti, Vanna Zanagnolo, Angelo Maggioni, Luca Savelli, Ugo De Giorgi, Fabio Landoni, Nicoletta Colombo, Nicoletta Colombo, Robert Fruscio, Robert Fruscio   +27 more
doaj   +1 more source

Surgical Removal of Residual Tumor Masses in Patients Undergoing Targeted Therapy for EGFR‐Mutated Locally Advanced or Metastatic Lung Cancer

International Journal of Cancer, EarlyView.
Non‐small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations often exhibit significant tumor reduction following tyrosine kinase inhibitor (TKI) therapy. Residual tumors frequently remain, however, leading to drug resistance and disease progression.
Fedor Moiseenko, Daniil Stroyakovskiy, Evgeniy Levchenko, Mikhail Fedyanin, Albina Gabina, Ani Oganesian, Sergey Belukhin, Maria Stepanova, Ekaterina Stepanova, Elizaveta Artemyeva, Alexander Myslik, Nikita Volkov, Alexei Bogdanov, Tatiana Shuginova, Kirill Kryukov, Valeria Kheinshtein, Arif Allakhverdiev, Ivan Zaberegniy, Yana Akhmadiyarova, Mikhail Popov, Anastasiya Danilova, Dmitriy Sehniaidze, Nikita Savelov, Nikita Levchenko, Evgeniy Slugin, Olga Lopushanskaya, Ekaterina Kuligina, Svetlana Aleksakhina, Aglaya Iyevleva, Alexandr Ivantsov, Vladimir Moiseyenko, Evgeny Imyanitov   +31 more
wiley   +1 more source

The German ONKOPEDIA Guideline for Myelofibrosis in 2025—Recommendations of an MPN Expert Panel of the German Society for Hematology and Oncology (DGHO)

International Journal of Cancer, EarlyView.
ABSTRACT The recently published ONKOPEDIA guideline on myelofibrosis, issued under the auspices of the German Society of Hematology and Oncology (DGHO), provides an updated, evidence‐based framework for the diagnosis and management of this rare, chronic myeloproliferative neoplasm.
Martin Griesshammer, Haifa Kathrin Al‐Ali, Gabriela M. Baerlocher, Konstanze Döhner, Steffen Koschmieder, Nicolaus Kröger, Petro E. Petrides, Dominik Wolf, Florian H. Heidel   +8 more
wiley   +1 more source

Oncologic outcomes after splenectomy during initial cytoreductive surgery in advanced epithelial ovarian cancer: a nationwide population‐based cohort study

Acta Obstetricia et Gynecologica Scandinavica, 2022
Introduction Epithelial ovarian cancer (EOC) patients undergoing splenectomy during cytoreductive surgery represent a small subgroup of patients. Splenic metastases or technical reasons due to extensive upper abdominal disease may require a splenectomy ...
Sherin A. Said, Maaike A. van derAa, Guus Veldmate, Joanne A. deHullu, Anne M. vanAltena   +4 more
doaj   +1 more source

α2,3‐Sialyltransferase (ST3Gal1) regulates endometrioid‐type epithelial ovarian cancer cell migration and invasion via VEGF‐R2/JAK2/STAT3 signaling cascades

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective To investigate the role of ST3 β‐galactoside α‐2,3‐sialyltransferase 1 (ST3Gal1) and vascular endothelial growth factor receptor 2 (VEGF‐R2) in endometrioid‐type epithelial ovarian cancer (E‐OC) because aberrant α2,3‐sialylation mediated by ST3Gal1 and VEGF‐R2‐related angiogenesis is linked with tumor progression. Methods ST3Gal1 and
Wei‐Ting Chao, Chia‐Hao Liu, Szu‐Ting Yang, Chen‐Hao Lin, Liang‐Wei Wang, Peng‐Hui Wang   +5 more
wiley   +1 more source

Systematic Pelvic and Paraaortic Lymph Node Dissection in Advanced Ovarian Cancer—Technical Aspects and Current Evidence-Based Data for Clinical Decision-Making

Surgical Techniques Development
Cytoreductive surgery in the context of a multidisciplinary approach, including adjuvant and neoadjuvant therapy (when indicated), aims ideally to obtain complete resection and represents the cornerstone for long-term survival in patients with advanced ...
Traian Dumitrascu
doaj   +1 more source

Results of Phase 1 study on cytoreductive radical prostatectomy in men with newly diagnosed metastatic prostate cancer

Prostate International, 2019
Background: Preclinical and retrospective data suggest that cytoreductive radical prostatectomy may benefit a subset of men who present with metastatic prostate cancer (mPCa).
Bertram E. Yuh, Young Suk Kwon, Brian M. Shinder, Eric A. Singer, Thomas L. Jang, Sinae Kim, Mark N. Stein, Tina Mayer, Anna Ferrari, Nara Lee, Rahul R. Parikh, Nora Ruel, Wun-Jae Kim, Shigeo Horie, Seok-Soo Byun, Thomas E. Ahlering, Isaac Yi Kim   +16 more
doaj   +1 more source